In the CML molecular context, point mutations on the ABL1 gene are also a challenge for clinical guidelines because several mutations are responsible for tyrosine kinase inhibitor resistance, indicating that a change may be necessary in the treatment protocol. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.